Page 21 - Viral Vector News Today

Heres what the World Health Organisation WHO) has to say on the issue of "Adverse events following immunization (AEFI)" for any vaccine: "As vaccine-preventable infectious diseases continue to decline, people have become increasingly concerned about the risks associated with vaccines. Furthermore, technological advances and continuously increased knowledge about vaccines have led to investigations focused on the safety of existing vaccines which have sometimes created a climate of concern. "Ad...

The growing global pipeline of cell and gene therapy projects has prompted Thermo Fisher Scientific to invest again, with it announcing today that it had bought Henogen, Novasep’s viral vector manufacturing business based in Belgium, for about US$879.72m (€725m) in cash.

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots? The unchecked advance of the coronavirus disease 2019 (COVID-19) has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An encouraging new preprint, that appeared on the bioRxiv* server shows the immunogenicity, safety, and protective efficacy, of a...

Atmospheric particulate matter may influence the transmission and evolution of SARS-CoV-2 A recent study conducted at the University of Malta Medical School, Malta, has revealed that a drop in the level of particulate matter 2.5 (PM2.5), which are airborne pollutant particles with a diameter of 2.5 micrometers, in the atmosphere due to lockdown is associated with the arrival of a newer variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has eventually displaced the or...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) ... CytoDel IncJanuary 7, 2021 GMT Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection Supports the Development of New Approaches to Treat Multiple Neurological Diseases NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) ...

EMMA HARRIS/STATESMAN FILE As the first round of COVID-19 vaccines reach New York, Stony Brook Medicine is informing the community about vaccine development and pushing to become a distribution center in Suffolk County within the coming months.  The Dean of the School of Medicine and Senior Vice President for Health Sciences, Kenneth Kaushansky, told the Faculty Senate on Dec. 7 that the hospital requested 9,600 doses of the vaccine to be administered to their staff, from the first batch from ...

Dubai: The creation of vaccines against COVID-19 has been a bioengineering feat setting a record in research, manufacture, approvals and administration. So far, we know that at least five active vaccinations (DNA, RNA, Viral Vector, Viral Subunit, Live attenuated, Inactivated, Virus Like Particles, Split Virus Vaccines, Ribonucleo Protein vaccine) have been created. In the passive vaccination variety, the monoclonal, polyclonal anti-bodies, the Convalescent Plasma and mRNA induced antibodies va...